78例乳腺癌改良根治术后pT3N0M0期患者放疗价值探讨

doi:10.3760/cma.j.issn.1004-4221.2017.10.009

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (1024 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract

Objective To investigate the value of post-mastectomy radiotherapy (PMRT) in patients with T₃N₀ breast cancer (BC) who were treated with modified radical mastectomy (MRM). Methods A retrospective analysis was performed on the clinical data of BC patients treated with MRM from 1997 to 2014.The inclusion criteria were as follows:(1) female patients;(2) pathological diagnosis of invasive BC;(3) tumor volume greater than 5 cm without axillary lymph node metastasis;(4) the patients who received no neoadjuvant chemotherapy or endocrine therapy and had no distant metastasis or other second primary cancers. A total of 78 patients met the inclusion criteria. Forty patients (51%) received PMRT and sixty-seven patients (86%) received adjuvant chemotherapy. The Kaplan-Meier method was used to calculate overall survival (OS), disease-free survival (DFS)(DFS), and local-regional recurrence (LRR) rates, and survival differences between groups were analyzed by the log-rank test. Results The median follow-up time was 79 months (6-232 months). For all patients, the 5-year OS, DFS, and LRR rates were 89%, 87%, and 2%, respectively. The 5-year DFS, OS and LRR rates for radiotherapy group were 84%, 84% and 0%, respectively, versus 91%(P=0.641), 96%(P=0.126), and 5% for non-radiotherapy group. Only estrogen receptor/progesterone receptor (ER/PR) status and molecular type had significant impacts on DFS (P=0.002 and 0.031, respectively). One patient in non-radiotherapy group had chest wall recurrence. Conclusions MRM is effective in reducing LRR in T₃N₀M₀ BC patients. Only ER/PR status and molecular type significantly influence DFS. Effective systemic therapy may be helpful for some T₃N₀ patients to avoid chest wall and supraclavicular radiotherapy after MRM, but large-sample studies are needed to further confirm this conclusion.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Li Shuai
	Wang Shulian
	Tang Yu
	Jin Jing
	Ren Hua
	Song Yongwen
	Wang Weihu
	Liu Yueping
	Fang Hui
	Liu Xinfan
	Yu Zihao
	Li Yexiong

Key words： Breast cancer/radiotherapy Local regional recurrence

Received: 20 April 2017

Fund:

Key Laboratory Projects of Xinjiang Uygur Autonomous Region (2015KL021)

Cite this article:

Li Shuai,Wang Shulian,Tang Yu et al. Clinical value of radiotherapy in 78 patients with pT₃N₀M₀ breast cancer after modified radical mastectomy[J]. Chinese Journal of Radiation Oncology, 2017, 26(10): 1151-1155.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.10.009 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I10/1151

[1] Goulart J,Truong P,Woods R,et al. Outcomes of node-negative breast cancer 5 centimeters and larger treated with and without postmastectomy radiotherapy[J].Int J Radiat Oncol Biol Phys,2011,80(3):758-764.DOI:10.1016/j.ijrobp.2010.02.014.
[2] Helinto M,Blomqvist C,Heikkil P,et al. Post-mastectomy radiotherapy in pT₃N₀M₀ breast cancer:is it needed?[J].Radiother Oncol,1999,52(3):213-217.DOI:10.1016/S0167-8140(99)00099-7.
[3] Senkus E,Kyriakides S,Ohno S,et al. Primary breast cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2015,26 Suppl 5:v8-v30.DOI:10.1093/annonc/mdv298.
[4] NCCN. Breast cancer 2016,version 2[EB/OL][2017-04-19].http://www.nccn.org.
[5] Yan WS,Christos P,Nori D,et al. Is there a cause-specific survival benefit of postmastectomy radiation therapy in women younger than age 50 with T₃N₀ invasive breast cancer? A SEER database analysis:outcomes by receptor status/race/ age:analysis using the NCI Surveillance,Epidemiology,and End Results (SEER) database[J].Am J Clin Oncol,2013,36(6):552-557.DOI:10.1097/COC.0b013e31825 d529b.
[6] Johnson ME,Handorf EA,Martin JM,et al. Postmastectomy radiation therapy for T₃N₀:a SEER analysis[J].Cancer,2014,120(22):3569-3574.DOI:10.1002/cncr.28865.
[7] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG),Davies C,Godwin J,et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials[J].Lancet,2011,378(9793):771-784.DOI:10.1016/S0140-6736(11)60993-8.
[8] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG),Peto R,Davies C,et al. Comparisons between different polychemotherapy regimens for early breast cancer:meta-analyses of long-term outcome among 100 000 women in 123 randomised trials[J].Lancet,2012,379(9814):432-444.DOI:10.1016/S0140-6736(11)61625-5.
[9] Floyd SR,Buchholz TA,Haffty BG,et al. Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger[J].Int J Radiat Oncol Biol Phys,2006,66(2):358-364.DOI:10.1016/j.ijrobp.2006.05.001.
[10] Alphonse GT,Jeong JH,Mamounas EP,et al.Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy,with or without adjuvant systemic therapy and without radiotherapy:results from five national surgical adjuvant breast and bowel project randomized clinical trials[J].J Clin Oncol,2006,24(24):3927-3932.DOI:10.1200/JCO.2006.06.9054.
[11] Overgaard M,Hansen PS,Overgaard J,et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy[J].N Engl J Med,1997,337(14):949-955.DOI:10.1056/NEJM199710023371401.
[12] Overgaard M,Jensen MB,Overgaard J,et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen:Danish Breast Cancer Cooperative Group DBCG 82c randomised trial[J].Lancet,1999,353(9165):1641-1648.DOI:10.1016/S0140-6736(98) 09201-0.
[13] Carey LA,Perou CM,Livasy CA,et al. Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study[J].JAMA,2006,295(21):2492-2502.DOI:10.1001/jama.295.21.2492.
[14] Nguyen PL,Taghian AG,Katz MS,et al. Breast cancer subtype approximated by estrogen receptor,progesterone receptor,and HER-2 is associated with local and distant recurrence after breast-conserving therapy[J].J Clin Oncol,2008,26(14):2373-2378.DOI:10.1200/JCO.2007.14.4287.